Evidence map›Paper›PMID 24719430›Full record

ArticleJournal of virology2014

Conserved neutralizing epitope at globular head of hemagglutinin in H3N2 influenza viruses.

Yoshitaka Iba, Yoshifumi Fujii, Nobuko Ohshima, Tomomi Sumida, Ritsuko Kubota-Koketsu, Mariko Ikeda, Motoaki Wakiyama, Mikako Shirouzu, Jun Okada, Yoshinobu Okuno and 2 more

Open access · bronzeAbstract read
In one paragraph

Article in Journal of virology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 55 papers.

0numbers the graph read from it
0cells of the map it votes in
55citing papers in PubMed
6.4field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

55 citing papers in PubMed, 83 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Article
  6. Article
  7. Review
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Review
  14. Article
  15. Article
  16. Next-Generation Influenza Vaccines.Cold Spring Harbor perspectives in medicine · 2021
    Review
  17. Review
  18. Article
  19. Article
  20. Antimicrobial agents and chemotherapy · 2021
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 4 institutions in 1 country.

Yoshitaka IbaInstitute for Comprehensive Medical Science, Fujita Health University, Toyoake, Aichi, Japan.
Yoshifumi FujiiRIKEN Systems and Structural Biology Center, Suehiro, Tsurumi, Yokohama, Japan.
Nobuko OhshimaInstitute for Comprehensive Medical Science, Fujita Health University, Toyoake, Aichi, Japan.
Tomomi SumidaRIKEN Systems and Structural Biology Center, Suehiro, Tsurumi, Yokohama, Japan.
Ritsuko Kubota-KoketsuDepartment of Virology, Research Institute for Microbial Diseases, Osaka University, Suita, Osaka, Japan.
Mariko IkedaRIKEN Systems and Structural Biology Center, Suehiro, Tsurumi, Yokohama, Japan.
Motoaki WakiyamaRIKEN Systems and Structural Biology Center, Suehiro, Tsurumi, Yokohama, Japan.
Mikako ShirouzuRIKEN Systems and Structural Biology Center, Suehiro, Tsurumi, Yokohama, Japan.
Jun OkadaSales and Marketing Division, Medical and Biological Laboratories Co., Ltd., Nagoya, Aichi, Japan.
Yoshinobu OkunoKanonji Institute, The Research Foundation for Microbial Diseases, Osaka University, Kanonji, Kagawa, Japan.
Yoshikazu KurosawaInstitute for Comprehensive Medical Science, Fujita Health University, Toyoake, Aichi, Japan kurosawa@fujita-hu.ac.jp.
Shigeyuki YokoyamaRIKEN Systems and Structural Biology Center, Suehiro, Tsurumi, Yokohama, Japan.
Systems Biology Institute · JPFujita Health University · JPOsaka University · JPMedical & Biological Laboratories (Japan) · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

unlabelledNeutralizing antibodies that target the hemagglutinin of influenza virus either inhibit binding of hemagglutinin to cellular receptors or prevent the low-pH-induced conformational change in hemagglutinin required for membrane fusion. In general, the former type of antibody binds to the globular head formed by HA1 and has narrow strain specificity, while the latter type binds to the stem mainly formed by HA2 and has broad strain specificity. In the present study, we analyzed the epitope and function of a broadly neutralizing human antibody against H3N2 viruses, F005-126. The crystal structure of F005-126 Fab in complex with hemagglutinin revealed that the antibody binds to the globular head, spans a cleft formed by two hemagglutinin monomers in a hemagglutinin trimer, and cross-links them. It recognizes two peptide portions (sites L and R) and a glycan linked to asparagine at residue 285 using three complementarity-determining regions and framework 3 in the heavy chain. Binding of the antibody to sites L (residues 171 to 173, 239, and 240) and R (residues 91, 92, 270 to 273, 284, and 285) is mediated mainly by van der Waals contacts with the main chains of the peptides in these sites and secondarily by hydrogen bonds with a few side chains of conserved sequences in HA1. Furthermore, the glycan recognized by F005-126 is conserved among H3N2 viruses. F005-126 has the ability to prevent low-pH-induced conformational changes in hemagglutinin. The newly identified conserved epitope, including the glycan, should be immunogenic in humans and may induce production of broadly neutralizing antibodies against H3 viruses. IMPORTANCE: Antibodies play an important role in protection against influenza virus, and hemagglutinin is the major target for virus neutralizing antibodies. It has long been believed that all effective neutralizing antibodies bind to the surrounding regions of the sialic acid-binding pocket and inhibit the binding of hemagglutinin to the cellular receptor. Since mutations are readily introduced into such epitopes, this type of antibody shows narrow strain specificity. Recently, however, broadly neutralizing antibodies have been isolated. Most of these bind either to conserved sites in the stem region or to the sialic acid-binding pocket itself. In the present study, we identified a new neutralizing epitope in the head region recognized by a broadly neutralizing human antibody against H3N2. This epitope may be useful for design of vaccines.

Indexed as

Amino Acid SequenceAntibodies, MonoclonalAntibodies, NeutralizingAntibodies, ViralBase SequenceEpitope MappingHemagglutinin Glycoproteins, Influenza VirusHumansInfluenza A Virus, H3N2 SubtypeInfluenza, HumanMolecular Sequence DataNeutralization TestsProtein ConformationSequence Homology, Amino AcidAntibodies, MonoclonalAntibodies, NeutralizingAntibodies, ViralHemagglutinin Glycoproteins, Influenza Virus

Identifiers

PMID24719430
PMCPMC4054433
OpenAlexW2054583440

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.